Response to Klintmalm on the use of generic immunosuppression

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 791-

  Latran, M ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; BIOEQUIVALENCE; DRUG EXPOSURE; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; ORGAN TRANSPLANTATION; PATIENT EDUCATION; PRIORITY JOURNAL;

DRUGS, GENERIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; TACROLIMUS;

EID: 84857646669     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03876.x     Document Type: Letter

References (5)

1. Klintmalm GB,. Immunosuppression, generic drugs and the FDA. Am J Transplant. 2011; 11: 1765-1766.
2. Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R,. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant. 2011; 11: 1861-1867.
3. Davit BM, Nwakama PE, Buehler GJ, et al,. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009; 43: 1583-1597.
4. Christians U, Klawitter J, Clavijo CF,. Bioequivalence testing of immunosuppressants: Concepts and misconceptions. Kidney Int Suppl. 2010; (115): S1-S7.
5. McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S,. A multicenter experience with generic tacrolimus conversion. Transplantation. 2011; 92: 653-657.